GlassScriptPhysician profile
Venkata Chinnakotla
NPI 1033559604
$3,733.35
in general payments reported to CMS, 2019-2025
35 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2022: $274 · 2023: $129 · 2024: $932 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,218 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.82 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $372.27 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $370.23 | 2022-2025 | Omnipod |
| Medtronic, INC. | $254.08 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Amgen INC. | $225.02 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $218.27 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $216.66 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sequel Med Tech, LLC | $163.54 | 2025 | Twiist |
| Cequr Corporation | $156.78 | 2022-2025 | Cequr Simplicity |
| Radius Health, INC. | $142.41 | 2019-2025 | Tymlos |
| Novo Nordisk INC | $140.79 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $126.15 | 2022-2025 | Synthroid |
| Alexion Pharmaceuticals, INC. | $115.25 | 2024-2025 | Strensiq |
| Ascensia Diabetes Care US INC. | $108.91 | 2024-2025 | |
| Corcept Therapeutics | $106.59 | 2024-2025 | Korlym |
| Medtronic Minimed, INC. | $103.92 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.55 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $89.23 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $83.69 | 2022-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $70.80 | 2024-2025 | Isturisa, Signifor Lar |
| Abbott Laboratories | $62.88 | 2024-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $61.31 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $52.97 | 2025 | |
| Antares Pharma, INC. | $50.30 | 2024-2025 | Xyosted |
| Chiesi USA, INC. | $43.97 | 2025 | Mycapssa, Myalept |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.70 | 2024-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $40.87 | 2024-2025 | |
| Almatica Pharma LLC | $35.50 | 2025 | Teriparatide |
| Madrigal Pharmaceuticals | $34.47 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $24.46 | 2022 | |
| Amneal Pharmaceuticals LLC | $24.26 | 2024 | Unithroid |
| Horizon Therapeutics Plc | $22.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.89 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $18.70 | 2024 | Imcivree |
| Ibsa Pharma INC. | $18.49 | 2025 | Tirosint, Flector, Licart |
| Astrazeneca Pharmaceuticals LP | $13.75 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkata Chinnakotla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.